1. Survival of stage IV melanoma in Belgium and the Netherlands.
- Author
-
Suijkerbuijk, K.P.M., Haanen, J.B.A.G., Boers‐Sonderen, M.J., Hospers, G.A.P., Blank, C.U., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Piersma, D., Aarts, M.J.B., van Rijn, R.S., Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., van der Veldt, A.A.M., and van den Eertwegh, A.J.M.
- Subjects
MELANOMA ,RESEARCH grants ,TRAVEL costs - Abstract
Dr Aarts has advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Prof vd Eertwegh has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis. Dr Suijkerbuijk has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, Abbvie and received honoraria from Novartis, MSD and Roche. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF